Workflow
ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates
PRPHProPhase Labs(PRPH) ZACKS·2024-11-13 15:15

Core Insights - ProPhase Labs, Inc. reported a quarterly loss of 0.35pershare,whichwasworsethantheZacksConsensusEstimateofalossof0.35 per share, which was worse than the Zacks Consensus Estimate of a loss of 0.31, and compared to a loss of 0.30pershareayearago,indicatinganegativeearningssurpriseof−12.900.30 per share a year ago, indicating a negative earnings surprise of -12.90% [1] - The company generated revenues of 3.15 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 11.56%, but down from 8.37millioninthesamequarterlastyear[2]−ProPhaseLabsshareshavedeclinedapproximately83.78.37 million in the same quarter last year [2] - ProPhase Labs shares have declined approximately 83.7% year-to-date, contrasting with a 25.5% gain in the S&P 500 [3] Earnings Outlook - The future performance of ProPhase Labs' stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - Current consensus EPS estimate for the upcoming quarter is -0.24 on revenues of 5.88million,andforthecurrentfiscalyear,itis−5.88 million, and for the current fiscal year, it is -1.23 on revenues of 14.8million[7]IndustryContext−TheMedical−Drugsindustry,towhichProPhaseLabsbelongs,iscurrentlyrankedinthetop2514.8 million [7] Industry Context - The Medical - Drugs industry, to which ProPhase Labs belongs, is currently ranked in the top 25% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Plus Therapeutics, is expected to report a quarterly loss of 0.46 per share, reflecting a year-over-year change of +54%, with revenues anticipated to be $1.4 million, up 12.9% from the previous year [9][10]